Clinical Trial Update: ARQ 197 in Subjects With Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial update for ARQ 197 (tivantinib) in patients with metastatic solid tumors; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ARQ 197 (tivantinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Cancer, Tumor | Phase 1 | Status: COMPLETED